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ABSTRACT 
Background: Coronary artery bypass grafting (CABG) with conventional cardiopulmonary bypass (CPB) 
induces systemic inflammation. Miniaturized CPB may attenuate systemic inflammatory activation. The 
intracellular signalling pathways promoting inflammation in cardiac surgery and the relative effects of CPB 
on these processes are uncertain. In this study, induction of reactive oxygen species (ROS) and activation of 
NF-κB, p38 mitogen activated protein kinase (MAPK) within leukocytes and leukocyte accumulation in 
cantharidin-induced blisters was compared in patients exposed to miniaturized (mCPB) or conventional CPB 
(cCPB). 
Methods: Patients undergoing CABG were randomised to receive either cCPB (n=13) or mCPB (n=13). Blood 
samples were collected pre-operatively and five times after initiating CPB (up to 5 hours) and analysed by 
flow cytometry for intracellular markers of activation (ROS, p38-MAPK and NF-κB phosphorylation). 
 
Results: ROS in lymphocytes were elevated in cCPB compared to mCPB (p<0.01) whereas ROS in 
granulocytes and monocytes were similar between groups.  Following initiation of CPB, p38-MAPK was 
higher in patients receiving cCPB compared to mCPB (p<0.05). NF-κB phosphorylation in leukocyte subsets 
was similar in patients exposed to cCPB or mCPB. Leukocyte accumulation in cantharidin-induced blisters, 
white cell counts and serum C-reactive protein were enhanced in response to cardiac surgery, but no 
differences were observed between mCPB or cCPB groups. Post-operative serum creatinine levels were 
reduced in the mCPB group compared to cCPB (p<0.05). 
Conclusion: Both p38-MAPK activation and ROS were attenuated with the use of mCPB compared to cCPB, 
providing a potential mechanism for reduced inflammation in association with CPB miniaturisation. 
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INTRODUCTION 
Coronary artery bypass grafting (CABG) is frequently performed with cardiopulmonary bypass (CPB). 
However, CPB is known to evoke a systemic inflammatory response[1]. Miniaturised CPB has been 
developed to attenuate systemic inflammation by optimising the components of the CPB circuit. 
Optimisation may be achieved through: reducing haemodilution by minimising the priming volume of the 
circuit; eliminating the blood-air-interface by avoiding the use of a venous reservoir; replacing the use of 
cardiotomy suction with a cell-salvage device; and coating the circuit with a biocompatible coating (e.g. 
phosphorylcholine), which would be expected to reduce contact activation.  In previous studies, mCPB has 
been shown to reduce blood loss and transfusion requirements[2, 3] and to lessen renal, myocardial and 
intestinal injury[2, 4, 5]. The inflammatory response has also been shown to be attenuated with the use of 
mCPB as demonstrated by reduced cytokine release and neutrophil activation[6-8]. Despite studies 
demonstrating that cardiac surgery with the use of CPB induces systemic inflammation, the pro- 
inflammatory signalling pathways activated by CPB have not been precisely defined. Moreover, the cell- 
signalling mechanisms underlying the inflammatory effects of CPB miniaturisation have not been 
characterised at a molecular level.  To address this question, a clinical trial to determine the kinetics of 
inflammatory signalling pathway activation was performed in patients undergoing CABG with conventional 
CPB (cCPB) or miniaturised CPB (mCPB).  The primary hypothesis was that, compared to cCPB, the mCPB 
system would reduce ROS / pro-inflammatory activation within leukocytes and attenuate systemic 
inflammation measured in blood samples. A secondary hypothesis was that the use of the mCPB system 
would reduce the degree of neutrophil and monocyte margination from within the circulation into fluid in 
the extravascular tissue compartment, harvested from cantharidin blisters. 
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MATERIALS AND METHODS 
 
Study design 
A single centre, parallel-group RCT was performed (ISRCTN30610605). A favourable local ethics opinion was 
obtained from the 'National Research Ethics Service, South West London’ Research Ethics Committee (REC 
reference 08/H0708/67). Informed written consent was obtained from research participants. 
 
Participants 
Patients undergoing primary isolated CABG by a single surgeon were considered. Patients <18 years of age; 
emergency surgery; ejection fraction <30%; recent cerebro-vascular accident; >75% carotid artery stenosis; 
renal impairment (serum creatinine >177 μmol/L); pre-existing coagulopathy, pre-existing liver dysfunction 
or recent (within 5 days) use of antiplatelet agents (aspirin/clopidogrel) were excluded. 
 
Intervention and comparator 
Anaesthesia was standardized for all patients. Thiopentone (1–3mg/kg) was used for induction with 3– 
5mg/kg fentanyl, and volatile agents were delivered in 50% air–O2 for maintenance. Propofol (3mg/kg/h) 
was infused during CPB and neuromuscular blockade was achieved using 0.1–0.15mg/kg pancuronium. 
Intravenous heparin (3 mg/kg) was used to maintain an activated clotting time >480s. 
Operations using cCPB or mCPB involved aortic cannulation, two-stage venous cannulation and moderate 
hypothermia (32°C) with parallel blood cell salvage (Electa, Sorin group, Milan, Italy). cCPB was conducted as 
described[9]. mCPB was conducted using the Sorin Dideco Extracorporeal Circulation Optimized (ECCO) 
system as described [10]. Coronary artery anastomoses were constructed using intermittent cross-clamp 
fibrillation (ICCF) as previously described[11]. 
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Outcome measures 
Primary outcome was intracellular ROS activation in granulocytes as these were considered the most rapid 
markers of pro-inflammatory signalling within the cell lineage first activated in acute inflammation[12]. 
 
Secondary outcomes were ROS activation in monocytes and lymphocytes; activation of pro-inflammatory 
p38 mitogen-activated protein kinase (MAPK) which promotes inflammation by activating downstream AP-1 
superfamily transcription factors [13] and activation of NF-κB transcription factor which activates multiple 
pro-inflammatory genes [14] measured as the phosphorylated p65 subunit. Secondary outcomes also 
included leukocyte counts in cantharidin-induced blisters, white cell counts, serum CRP and creatinine levels. 
Sampling times are summarised in Figure 1. 
 
Assays of intracellular ROS, p38-MAPK activation and NF-κB activation 
ROS were measured by combining (1:10) diluted blood with 3’-(p-aminophenyl) fluorescein (APF; Molecular 
Probes, Eugene, OR, USA)for 30 min at 37˚C prior to erythrocyte lysis.   In parallel, leukocytes were fixed with 
phosphatase buffers and isolated using erythrocyte lysis and centrifugation using manufacturer-published   
BD phosflow methods prior to incubation with phycoerythrin (PE)-Cy7-conjugated antibodies that recognise 
phosphorylated p38-MAPK and PE-conjugated antibodies that recognise Ser529 phosphorylated NF-κB (BD 
Biosciences, San Jose, CA, USA). Fluorescence was quantified in granulocytes, monocytes or lymphocytes 
(forward and side scatter) using flow cytometry and Summit 4.3 software. 
 
Quantitation of leukocyte migration 
Cantharidin was applied to the forearm to generate a blister, and leukocyte sub-populations in blister fluid 
were identified and counted using the Diff-Quick kit (Polysciences Inc , Warrington, PA, USA) and 
microscopy as described [9]. 
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Sample size 
Although the primary outcome was intracellular ROS activation in leukocytes, the target sample size was 
calculated on the basis of counts of post-operative leukocytes in cantharidin blisters, adjusted for baseline 
levels. We did this because the latter measurements were only made before and after the intervention 
(rather than having multiple post-operative measurements). Hence, the trial had less statistical power for 
this outcome than outcomes measured in blood samples.  Based on a previous study[9], we aimed for a 
sample size of 13 patients per group. We calculated that this sample size would have 95% power to detect a 
difference in means of 1.448 × 105 cells between groups, based on following assumptions: common standard 
deviation=1 × 105 with a 0.05 two-sided significance level. A power calculation for signalling outcomes 
(relating to ROS, p38 and p65/NF-κB) was not carried out in advance because the correlations between pre- 
and post-, and between longitudinal post-intervention measurements were unknown. 
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Randomisation 
Participants were randomised by the Imperial College Trial Unit staff not otherwise involved in the study. Random 
allocations were blocked and generated by computer. The random allocations were concealed at the time of 
recruitment.  Randomisation was carried out by one of the investigators after the patient’s eligibility had been 
checked and written informed consent obtained. Participants were blinded to the allocation. 
 
Statistical methods 
Data were analysed according to a pre-specified statistical analysis plan (SAP). Final analyses were  performed 
after all subjects completed the study and after the database was locked.  Continuously scaled outcomes are 
described as means and SD for each treatment group, at all time points if measured more than once. A natural 
logarithm transformation was applied if outcome data were positively skewed, in which case findings are reported 
on the natural logarithm scale. 
The effects of mCPB compared to cCPB were estimated by fitting mixed regression models (using STATA v.11.2) to 
take into account the repeated measurements. The following predictors were included: main effect of time, fitted 
categorically (baseline to 4 days after the operation depending on the measurement schedule for the variable) and 
main effect of the intervention (mCPB vs.cCPB). Interactions between treatment group and time were also fitted 
and, if statistically significant at the 5% level, differences between groups with 95% confidence intervals (CI) are 
described for each time point separately; otherwise an overall treatment difference (with 95% CI) is reported. All 
data analyses were performed on an intention-to-treat basis irrespective of the final actual treatment modality 
received. 
 
RESULTS 
Patient recruitment 
The flow of participants through the trial is described in the CONSORT diagram (Figure 2). Fifty patients 
undergoing CABG with CPB were considered for inclusion into the study. 7 declined to take part, 17 were 
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ineligible. 26 patients were randomised to mCPB (n=13) or cCPB (n=13).  All patients allocated to cCPB had 
surgery performed as allocated. One participant allocated to mCPB underwent surgery with cCPB because 
the perfusionist was not fully trained to use mCPB. 
 
Baseline characteristics and operative details 
Patient characteristics and peri- and post- operative data are summarised in Table 1 and Table 2. 
 
Primary and secondary outcomes 
ROS activation 
Distributions for ROS, p38 and p65 were positively skewed and the data were transformed into natural 
logarithms. Effect estimates for the comparison between mCPB and cCPB groups are presented in Table 3. 
ROS induction levels in lymphocytes were higher in patients exposed to cCPB compared to mCPB at 30 min 
(mean difference= -0.39 log units, 95% CI [-0.69 to -0.09], p=0.01; Table 3). ROS 
induction levels in granulocytes (the primary outcome) and mononuclear cells showed the same 
pattern as for ROS levels in lymphocytes but the differences between groups were not statistically significant 
(Table 3, Figure 3A, Figure 4A). 
 
p38-MAPK and NF-κB activation 
Distributions for p38-MAPK and NF-κB p65 were also positively skewed and the data were transformed into 
natural logarithms.  Activation of p38-MAPK peaked at the time of initiation of cCPB (t=0 timepoint) and 
subsequentlydeclined throughout surgery (Figure 3B, Figure 4B). Activation of p38-MAPK in granulocytes 
was lower in patients exposed to mCPB compared to cCPB (mean difference= 0.47 log units, 95% CI -0.89 to - 
0.05, p=0.03; Table 3, Figure 3B, Figure 4B). A reverse pattern was observed in mononuclear cells, with p38- 
MAPK being enhanced, but not significantly, in patients exposed to mCPB compared to cCPB (Table 3, Figure 
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3B, Figure 4B). Activation of NF-κB p65 in granulocytes and mononuclear cells did not differ between  
groups; levels were reduced in response to cardiac surgery irrespective of group, with the lowest levels were 
observed at 2h and 5h following the start of CPB (Table 3, Figure 3C, Figure 4C). 
 
Leukocyte migration, white cell counts, haemoglobin, creatinine and C-reactive protein 
WCC, Hb, Creatinine and CRP data are summarised in Table 4. Summary statistics for leukocyte counts in 
cantharidin blisters are given in Table 5. Representative light microscopy images are illustrated in Figure 5. 
There were no significant differences between mCPB and cCPB in leukocyte migration into skin blisters (Table 
3).  No differences in white cell counts in peripheral blood or haemoglobin were observed between either CPB 
groups (Table 3, Figure 6B and D). Serum creatinine levels were lower in the mCPB compared to the cCPB 
group and there was a significant time by group interaction, (p=0.04) despite the treatment effects at day 1 
and day 4 days after the operation being individually non-significant (these estimates were in opposite 
directions; Table 3 and Figure 6C). CRP levels increased on day 1 and were further enhanced on day 4 following 
surgery, with no difference between either the mCPB or cCPB groups (Table 3, Figure 6A). 
 
DISCUSSION 
 
Main findings 
Coronary revascularisation with mCPB compared to cCPB induced a lower early rise (at 30 minutes) in ROS in 
lymphocytes; levels of ROS in granulocytes or monocytes changed in a very similar manner but differences 
between groups were not significant.  Activation of p38-MAPK in granulocytes was lower in patients exposed 
to mCPB compared to cCPB but not in mononuclear cells. There were no differences in NF-κB activation 
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between the mCPB and cCPB groups. Despite the differing characteristics of p38-MAPK and ROS activation, 
the total numbers of migrating leukocytes into tissues did not differ between the two groups. There were 
also attenuated serum creatinine levels in the mCPB group. 
 
Effects of CPB miniaturisation on leukocyte activation 
Our institution has developed extensive experience with mCPB, proven to be safe and effective[10].  mCPB has 
been associated with lower levels of inflammatory cytokines including IL-6[15-17], IL-8[6], TNFα[16], MCP-1[15] 
and neutrophil elastase [6, 16] suggesting less immune activation compared to conventional systems.  In 
addition, levels of oxidative stress, indicated by elevated malondialdehyde levels, were lower in mCPB 
patients[18]. Here we compared the effects of CPB systems on pro-inflammatory 
signalling molecules. We chose to study the activation of signalling molecules in leukocytes because they 
can act as rapid sentinels of the inflammatory response. 
p38 -MAPK activation in granulocytes was significantly reduced in patients exposed to mCPB compared to 
cCPB. By contrast, p38-MAPK actiation in mononuclear cells, ROS induction and NF-κB activity in both 
granulocytes and mononuclear cells was similar between both groups. We conclude from these data that  
mCPB had specific inhibitory effects on p38-MAPK activation in granulocytes.  Interestingly, mCPB and cCPB 
were associated with comparable numbers of leukocytes migrating into blisters and equivalent numbers of 
circulating white blood cells.  
 
What is uncertain is the reactivity of those leukocytes within the tissue compartment. As an adaptive response 
to injury, further work is required to understand the transition between inflammation, resolution and healing.  
Our data is in keeping with other clinical studies showing preservation of renal function[2]. Whether this is due 
to the mCPB intervention is uncertain. 
 
We have shown that coronary surgery with ICCF leads to the activation by phosphorylation of p38-MAPK, an 
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inflammatory signalling intermediary, in leukocytes and induction of ROS. The ICCF technique is standard 
practice in our institution but is used less frequently elsewhere and previously shown to be as effective as 
other methods of myocardial protection[19]. We believe our manuscript is the first to report ROS, p38- 
MAPK and NF-κB changes in surgery with ICCF. The effects of cardioplegic arrest on pro-inflammatory 
leukocyte signalling and different modalities of cardiac surgery, such as valvular surgery, are unknown. 
However, the leukocyte-specific effects shown in this trial may apply to other non-coronary cardiac surgical 
 
scenarios. 
 
Limitations 
This study was not powered for clinical observations and conclusions cannot be drawn about 
the relative effects of different methods of CPB on specific parameters of organ injury. The trial may also 
have had insufficient power for the primary outcome. With hindsight, the decision to power the trial on cell 
counts for the cantharidin blisters, rather than the primary outcome, may have been sub-optimal. The logic 
for this decision was reasonable but the large target difference in cell counts (1.5 standard 
deviations) may have been over-optimistic, even though based on pilot data).. Using the relevant 
correlations observed in the trial, we can now know that the trial was only able to detect a relatively large 
standardised difference in ROS in granulocytes (about 0.85 standard deviations) with 90% power and a 2- 
tailed significance level of 0.05. 
 
Despite randomisation, diabetes was higher in cCPB which could, in principle, influence the parameters of 
inflammation assayed in this study. The operating, anaesthetic and perfusion staff were not blinded to 
allocations which, in theory, may have introduced unconscious performance biases. 
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However, aortic cross-clamp and total CPB exposure times for both cCPB and mCPB were similar in both 
randomised groups., which provides some evidence that the surgery proceeded in the same way apart from 
the method of CPB. Operativedifferences between groups were minimised by ensuring that all operations 
were carried out by a single surgeon. Aspirin may influence cell signalling in patients and anti-platelet use 
was an exclusion criteria. The pro-inflammatory signalling response of mCPB with concurrent aspirin 
treatment is unknown and is aconsideration for future studies. 
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CONCLUSION 
Cardiac surgery with mCPB was associated with attenuation of pro-inflammatory intracellular signalling 
responses in leukocytes, measured by ROS and activation of p38-MAPK compared to cCPB. Accumulation of 
activated leukocytes into tissues and late markers of inflammation were equivalent between groups despite 
the alterations in signalling seen with mCPB. 
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FIGURE LEGENDS 
Figure 1: Summary of blood and blister fluid sampling times. 
Blood and cantharidin-induced skin blister fluid were sampled in patients exposed to cCPB or mCPB. A 
time- line is presented to summarise sampling times. 
 
Figure 2: Overview of participant selection. 
Trial participants were recruited and assessed for exclusion criteria. Computer randomisation 
allocated participants to either mCPB (investigative group) or cCPB (control group). 
 
Figure 3: Effect of CPB on ROS induction and phosphorylation of p38-MAPK and phosphorylation of NF-
κB p65 
CABG was performed with cCPB or mCPB. Peripheral blood samples were collected prior to surgery, 
post- induction (Post Ind), immediately prior to CPB (0 minutes) and at varying times following 
CPB initiation. Samples were stained using a ROS-sensitive dye (APF; A) antibodies that recognise 
phosphorylated p38- MAPK (B) or antibodies that recognise Ser529 phosphorylated NF-κB (C). 
Fluorescence of leukocyte cell subpopulations was quantified by flow cytometry after subtracting 
values from isotype-control antibodies. Data were pooled and log-transformed. Mean fluorescence 
intensity (MFI) values ± SD are shown with arbitrary units (AU). 
Figure 4: Modelled data on log-transformed measurements of ROS, p38-MAPK and NF-κB p65 
 
CABG was performed with cCPB or mCPB. Peripheral blood samples were collected prior to surgery, 
post- induction, immediately prior to CPB (0 minutes) and at varying times following CPB 
initiation. (A) ROS induction (B) phosphorylation of p38-MAPK or (C) phosphorylation at Ser529 of 
NF-κB p65 subunits was measured. Data were log-transformed the effects of CPB were estimated by 
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fitting mixed regression models. Mean fluorescence intensity (MFI) values ± SD are shown with 
arbitrary units (AU). 
 
Figure 5: Extravasation of leukocytes into cantharidin skin blisters 
CABG was performed with cCPB or mCPB. Blister fluid samples were collected prior to surgery 
(Baseline) and at 5 h following CPB initiation (post-operative). Cells were collected, stained using 
Diffquick and visualised by microscopy. Representative images are shown at ×40 optical magnification. 
 
Figure 6: Summary of perioperative changes in CRP, White cell count, creatinine and haemoglobin 
clinical parameters 
CABG was performed with cCPB or mCPB. Blood was sampled prior to surgery (baseline) and on the first 
and fourth days following surgery. Log-transformed data for (A) CRP, (B) white cell counts, (C) serum 
creatinine and (D) haemoglobin are presented ±SD. 
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Table 1. Patient characteristics 
Values  are  expressed  as  mean  with  standard  deviation  or  number  with  percentage  in  parentheses  as 
indicated. 
 
Variable mCPB (n=13) cCPB (n=13) 
Female (n) 5 (38.4%) 3 (23.1%) 
Age (years) 68.4 ± 6.8 66.3 ± 8.1 
Body Mass Index (kg/m2) 29.74 ± 4.53 29.31 ± 4.11 
Logistic euroSCORE 3.35 ± 2.36 3.74 ± 3.14 
Coronary vessel disease 
Single vessel disease 
Two vessel disease 
Three vessel disease 
 
0 
1 (8%) 
12 (92%) 
 
1 (8%) 
1 (8%) 
11 (84%) 
Angina Status 
Asymptomatic 
CCSI 
CCS II 
CCS III 
CCS IV 
 
1 (8%) 
0 
10 (77%) 
1 (8%) 
1 (8%) 
 
1 (8%) 
0 
7 (54%) 
3 (23%) 
2 (15%) 
Previous MI 3 (23%) 4 (31%) 
Ejection fraction 
Good >50% 
Fair 30-50% 
Poor <30% 
 
11 (85%) 
2 (15%) 
0 
 
12 (92%) 
1 (8%) 
0 
Diabetes 
Not diabetic 
Diet controlled 
Oral Therapy 
Insulin 
 
11 (85%) 
0 
1 (8%) 
1 (8%) 
 
6 (46%) 
0 
5 (38%) 
2 (15%) 
 
Smoking status 
Never smoked 
Current smoker 
Ex-smoker 
 
 
6 (46%) 
1 (8%) 
6 (46%) 
 
 
6 (46%) 
0 
7 (54%) 
Hypertension 
Treated for BP>140/90 
 
12 (92%) 
 
12 (92%) 
Chronic lung disease 
No 
Yes 
 
11 (85%) 
2 (15%) 
 
12 (92%) 
1 (8%) 
Extracardiac arteriopathy 
No 
Yes 
 
12 (92%) 
1 (8%) 
 
12 (92%) 
1 (8%) 
Pre-operative cardiac rhythm 
Sinus rhythm 
Atrial fibrillation/flutter 
 
11 (84%) 
1 (8%) 
 
12 (92%) 
1 (8%) 
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Table 2. Peri- and post-operative data 
Values  are  expressed  as  medians  with  inter-quartile  range  (IQR)  or  means  with  standard  deviation  or 
number with percentage in parentheses, as indicated. 
 
 
Variable mCPB (n=13) cCPB (n=13) 
Cardiopulmonary bypass time (min) 71 (IQR 62-84) 74 (IQR 67-91) 
Total cross clamp time (min) 30 (IQR 24-33) 34 (IQR 29-38) 
Number of coronary artery grafts 3.23 ± 0.62 3.23 ± 0.93 
Transfusions in first 24 hours 
Packed red cells (units) 
Platelets (pools) 
Fresh frozen plasma (pools) 
 
1.07 ± 1.38 
0.15 ± 0.37 
0.54 ± 1.05 
 
1.15 ± 1.57 
0.38 ± 0.51 
0.46 ± 1.13 
Time in ITU (days) 0.86 (IQR 0.80-1.33) 1.00 (IQR 0.80-1.10) 
Hospital stay (days) 8 (IQR 5-11) 8 (IQR 7-13) 
Post-operative neurological 
dysfunction 
No 
 
 
 
13 (100%) 
 
 
 
13 (100%) 
Haemofiltration post-operatively 
No 
 
13 (100%) 
 
12 (92%) 
Infective complications 
None 
Harvest site infection 
Sternal wound infection 
 
13 (100%) 
0 
0 
 
10 (77%) 
1 (8%) 
2 (15%) 
Return to theatre 
No re-operation 
Return for bleeding 
 
13 (100%) 
0 
 
13 (100%) 
0 
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Table 3. Treatment effects of mCPB vs cCPB for primary and secondary endpoints 
aFITC Mean Fluorescent Intensity (MFI) / arbitrary units (AU); bPE-Cy7 MFI/AU; cPE MFI/AU; dcell counts per 
blister (×105).  Other units otherwise indicated. *p-value for test of interaction of group and time. 
 
 
 
 
 
 
 
 
  Difference between mCPB 
and cCPB (log units) 
 
95% Confidence Interval 
 
p value 
Pr
im
ar
y ROS in granulocytesa -0.053 -0.26 to 0.15 0.62 
Se
co
nd
ar
y 
ROS in monocytesa 0.010 -0.31 to 0.33 0.95 
ROS in lymphocytesa  
-0.092 
 
-0.40 to 0.21 
 
0.03* 0 mins 
30 mins --0.390 -0.69 to -0.09 0.55 
60 mins -0.096 -0.40 to 0.21 0.01 
120 mins 0.049 -0.25 to 0.35 0.53 
300 mins -0.006  0.75 
-0.31 to 0.30 0.97 
p38 in granulocytesb -0.469 -0.89, to -0.05 0.03 
p38 in mononuclear cellsb 0.493 -0.40, to 1.39 0.28 
p65 in granulocytesc 0.052 -0.24, to 0.35 0.73 
p65 in mononuclear cellsc 0.171 -0.29, to 0.63 0.47 
Cantharidin blister polymorphonuclear 
cell countd 
0.700 -0.34, to 1.74 0.17 
Cantharidin blister mononuclear cell 
countd 
0.329 -0.39, to 1.05 0.34 
White cell count (×109/L) 0.064 -0.07, to 0.20 0.36 
Haemoglobin (g/dL) -0.037 -0.10, to 0.02 0.23 
Creatinine (µmol/L) -  
-0.-14 to 0.24 
0.04* 
Day 1 Creatinine (µmol/L) 0.050 0.61 
Day 4 Creatinine (µmol/L) -0.139 -0.33 to 0.05 0.16 
C-reactive protein (mg/mL) 0.135 -0.49, to 0.76 0.67 
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Table 4. White Blood Cell Count (WCC), Haemoglobin (Hb), Creatinine and C-Reactive Protein (CRP) 
Values indicated are mean ±SD. 
 
 
CRP (mg/mL)  
Time 
WCC (×109/L) L) Creatinin     
 mCPB cCPB mCPB cCPB mCPB cCPB mCPB cCPB 
Baseline 7.2 ± 1.4 7.8 ± 1.2 13.4 ± 1.1 13.2 ± 1.2 82.2 ± 1.3 93.8 ± 1.3  3 ± 2.67 2.27 ± 2.62 
Day 1 10.1 ± 1.2 9.2 ± 1.3 9.6 ± 1.1 10.0 ± 1.1 73.3 ± 1.3 80.0 ± 1.4 44.  08 ± 1.95 29.87 ± 6.05 
Day 4 8.6 ± 1.3 8.9 ± 1.3 10.1 ± 1.1 10.3 ± 1.2 79.8 ± 1.3 103.3 ± 1.6  .08 ± 1.65 179.75 ± 1.53 
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Table 5. Polymorphonuclear and mononuclear cantharidin blister cell counts 
Values presented are means ± SD (×105 cells per blister). 
 
 
count  
 
Time 
Polymorphonuclear cell 
count 
  
 mCPB cCPB mCPB cC PB 
 
 
Baseline 
 
 
2.72 ± 3.08 
 
 
3.15 ± 3.84 
 
 
1.70 ± 1.54 2.06 
 
 
± 2.94 
 
Post- 
operative 
 
 
44.29 ± 2.63 
 
 
22.58 ± 3.17 
 
 
21.99 ± 1.51 15.73 
 
 
± 2.05 
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